Trial Profile
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ramipril (Primary) ; Valsartan (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- Acronyms AIM-3
- 18 Feb 2016 According to ClinicalTrials.gov record, the primary endpoint has been amended.
- 17 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 10 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.